MedPath
FDA Approval

Ceftriaxone

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
September 30, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ceftriaxone(2 g in 1 1)

Registrants1

Companies and organizations registered with the FDA for this drug approval, including their contact information and regulatory details.

ACS Dobfar SPA

429243025

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

ACS Dobfar SpA

Fresenius Kabi USA, LLC

ACS Dobfar SPA

440886261

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ceftriaxone

Product Details

NDC Product Code
63323-347
Application Number
ANDA065329
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS, INTRAMUSCULAR
Effective Date
September 30, 2023
Code: 023Z5BR09KClass: ACTIMQuantity: 2 g in 1 1

Ceftriaxone

Product Details

NDC Product Code
63323-345
Application Number
ANDA065329
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS, INTRAMUSCULAR
Effective Date
September 30, 2023
Code: 023Z5BR09KClass: ACTIMQuantity: 500 mg in 1 1

Ceftriaxone

Product Details

NDC Product Code
63323-346
Application Number
ANDA065329
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS, INTRAMUSCULAR
Effective Date
September 30, 2023
Code: 023Z5BR09KClass: ACTIMQuantity: 1 g in 1 1
© Copyright 2025. All Rights Reserved by MedPath